• Net sales amounted to MSEK 0,0 (0,0)

• Operating profit/loss amounted to MSEK -5,8 (-6,2)

• Earnings per share * SEK -0.39 (-0.42)

• Cash and cash equivalents at the end of the period amounted to MSEK 6,6 (0,0)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 14,909,545 For the comparison period, the average number of shares was 14,752,833. Amounts in brackets refer to the corresponding period last year.

• Net sales amounted to MSEK 0,0 (0,0)

• Operating profit/loss amounted to MSEK -1,9 (-2,0)

• Earnings per share * SEK -0.13 (-0.13)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 14,920,478. For the comparison period, the average number of shares was 14,752,833. Amounts in brackets refer to the corresponding period last year.

CEO's comment

DexTech is currently working accordingly to the company's primary goal, to enter into an agreement with a licensee before the year-end 2020 for the company's drug candidate for treatment of skeletal metastases in advanced prostate cancer (mCRPC), OsteoDex.

The OsteoDex phase IIb study ends in April and final follow-up results from the study will be presented in May 2020. The results present information of whether the patient is alive or deceased (so-called OS, overall survival) and are based on patients followed 24 months after discontinuing OsteoDex treatment. Interim results as of February 18 show significantly prolonged survival for patients that responded to the treatment compared to the others. The results indicate prolonged survival after OsteoDex treatment.

The measure of overall survival is of great importance to potential stakeholders and can be crucial to the possibility of forming a licensing deal. A handful big pharma companies interested in OsteoDex have notified that they are awaiting the final results for overall survival that will be presented in May 2020.

The formal clinical study report (CSR) for the phase IIb study was available in December 2018. The results show that OsteoDex acts as a brake medicine at mCRPC. The course of the disease in the skeleton was stabilized in the majority of patients who completed the entire treatment. The study also confirmed the results of phase I i.e. OsteoDex has a very high tolerability with the absence of serious side effects. The fundamental goal of mCRPC treatment is to be life prolonging with acceptable side effects.

The preferential rights issue completed in the summer of 2019 in July 2019, which provided the company with SEK 9.2 million after issue costs, provides the company with a solid capital base that finances the license negotiations, including legal costs, and ensures the company's continued R&D.

Concerning the current Corona pandemic, the Company is much less affected than other companies. With finished clinical studies and a very low burn-rate, the company is very persistent during these circumstances. The situation provided by the Corona pandemic in form of closed societies does slow down dialogues with companies interested in OsteoDex. Here is our persistence, once again, very useful.

Anders R Holmberg
CEO

Contact

Anders Holmberg, CEO, +46 73 324 27 82

Gösta Lundgren, CFO, +46 70 710 47 88

This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on May 6, 2020 through the care of the above contact persons.